Cardiol Therapeutics (CRDL) Net Cash Flow: 2020-2024
Historic Net Cash Flow for Cardiol Therapeutics (CRDL) over the last 5 years, with Dec 2024 value amounting to -$4.6 million.
- Cardiol Therapeutics' Net Cash Flow rose 59.06% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $32.3 million, marking a year-over-year change of. This contributed to the annual value of -$4.6 million for FY2024, which is 75.69% up from last year.
- Cardiol Therapeutics' Net Cash Flow amounted to -$4.6 million in FY2024, which was up 75.69% from -$18.8 million recorded in FY2023.
- In the past 5 years, Cardiol Therapeutics' Net Cash Flow ranged from a high of $55.8 million in FY2021 and a low of -$21.0 million during FY2022.
- Its 3-year average for Net Cash Flow is -$14.8 million, with a median of -$18.8 million in 2023.
- As far as peak fluctuations go, Cardiol Therapeutics' Net Cash Flow skyrocketed by 948.48% in 2021, and later plummeted by 137.72% in 2022.
- Cardiol Therapeutics' Net Cash Flow (MRY) stood at $5.3 million in 2020, then soared by 948.48% to $55.8 million in 2021, then crashed by 137.72% to -$21.0 million in 2022, then rose by 10.86% to -$18.8 million in 2023, then surged by 75.69% to -$4.6 million in 2024.
- Its Net Cash Flow stands at -$4.6 million for FY2024, versus -$18.8 million for FY2023 and -$21.0 million for FY2022.